Highlights from Studies in Cardiovascular Disease Prevention Presented at the Digital 2020 European Society of Cardiology Congress: Prevention Is Alive and Well.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

15 citing papers in PubMed, 21 citations in OpenAlex.

1. Icosapent ethyl therapy for very high triglyceride levels: a 12-week, multi-center, placebo-controlled, randomized, double-blinded, phase III clinical trial in China.Lipids in health and disease · 2023
   Trial
2. Home-based transcutaneous electrical acupoint stimulation for high-normal blood pressure: A randomized controlled trial.Journal of clinical hypertension (Greenwich, Conn.) · 2022
   Trial
3. Systolic blood pressure time in target range within 24 hours and incident heart failure: insights from the real-world setting.Hypertension research : official journal of the Japanese Society of Hypertension · 2025
   Article
4. Diagnostic value of triglyceride-rich lipoprotein cholesterol for coronary artery lesions and its predictive significance for long-term prognosis in elderly patients with coronary heart disease.Frontiers in cardiovascular medicine · 2025
   Article
5. Apolipoprotein-CIII O-Glycosylation Is Associated with Micro- and Macrovascular Complications of Type 2 Diabetes.International journal of molecular sciences · 2024
   Article
6. A Systematic Review of the Randomized Controlled Trials of Gemcabene and Its Therapeutic Uses.Cureus · 2023
   Review
7. New Therapeutic Approaches in Treatment of Dyslipidaemia-A Narrative Review.Pharmaceuticals (Basel, Switzerland) · 2022
   Review
8. The Burden of Cardio-Cerebrovascular Risk Factors: Differences Between Individual Risk and Population Risk.High blood pressure & cardiovascular prevention : the official journal of the Italian Society of Hypertension · 2021
   Article
9. Nuclear Receptors and Clock Components in Cardiovascular Diseases.International journal of molecular sciences · 2021
   Review
10. Highlights from Studies Presented at the Virtual American College of Cardiology Scientific Sessions 2021: Staying Updated with the Latest Advancements in Prevention.Current atherosclerosis reports · 2021
    Review
11. Renin-Angiotensin System Blockers and the Risk of COVID-19-Related Mortality in Patients with Kidney Failure.Clinical journal of the American Society of Nephrology : CJASN · 2021
    Observational
12. COVID-19 and thrombosis: From bench to bedside.Trends in cardiovascular medicine · 2021
    Review
13. Highlights from Studies Presented at the American Heart Association Scientific Session 2020: Navigating New Roads in Prevention.Current atherosclerosis reports · 2021
    Review
14. Current Management Guidelines on Hyperlipidemia: The Silent Killer.Journal of lipids · 2021
    Review
15. Renin-angiotensin-aldosterone system blockers and region-specific variations in COVID-19 outcomes: findings from a systematic review and meta-analysis.Therapeutic advances in drug safety · 2021
    Article

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

Authors and funding

6 authors at 4 institutions in 1 country.

Funding

No grant is acknowledged in the PubMed record.

Abstract

Indexed as